When Was Ozempic Released? The Complete FDA Timeline and What Most Sources Get Wrong About Its Approval

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide injection) received FDA approval on December 5, 2017, exclusively for type 2 diabetes treatment at 0.5 mg and 1 mg doses
• The 2 mg dose received supplemental approval on March 16, 2022, expanding the therapeutic range but still only for diabetes
• Wegovy (same molecule, different dosing) received separate FDA approval June 4, 2021 for chronic weight management, which triggered the cultural explosion
• The 4-year gap between Ozempic's diabetes approval and its off-label weight-loss popularity is the most misunderstood part of the timeline

Direct answer (40-60 words)

Ozempic received FDA approval on December 5, 2017 for type 2 diabetes treatment. The initial approval covered 0.5 mg and 1 mg weekly doses. A supplemental approval for the 2 mg dose followed on March 16, 2022. Ozempic has never received FDA approval for weight loss, though its sister drug Wegovy (approved June 2021) targets obesity specifically.

Table of contents

1. The official FDA approval dates: what actually happened when
2. What most articles get wrong about the approval timeline
3. The critical difference between Ozempic approval and Wegovy approval
4. Why the drug existed years before the cultural phenomenon
5. The European and international approval timeline
6. The 2022-2024 shortage crisis and how it changed prescribing
7. Compounded semaglutide: when it became legal and why
8. The dose escalation timeline patients actually experience
9. Patent expiration dates and what happens in 2031
10. The FormBlends clinical pattern: how approval dates affect patient expectations
11. FAQ
12. Sources

The official FDA approval dates: what actually happened when

The FDA approval history for semaglutide products follows a specific sequence that most summary articles conflate:

Date	Product	Indication	Doses approved	FDA application number
December 5, 2017	Ozempic (semaglutide injection)	Type 2 diabetes	0.5 mg, 1 mg weekly	NDA 209637
September 2019	Rybelsus (oral semaglutide)	Type 2 diabetes	7 mg, 14 mg daily	NDA 213051
June 4, 2021	Wegovy (semaglutide injection)	Chronic weight management	2.4 mg weekly	NDA 215256
March 16, 2022	Ozempic 2 mg	Type 2 diabetes (supplemental)	2 mg weekly added	sNDA 209637/S-022

The confusion stems from three facts:

1. Same molecule, different products. Ozempic and Wegovy contain identical semaglutide. The FDA treats them as separate drugs because the dosing regimen, indication, and clinical trial programs differ.

1. The approval date is not the popularity date. Ozempic existed for nearly four years before the 2021 TikTok and celebrity-driven weight-loss surge. The drug was available, prescribed, and working during that entire window, but almost exclusively for diabetes patients.

1. The 2 mg Ozempic dose came after Wegovy. By the time Ozempic received approval for the 2 mg dose in March 2022, Wegovy had already been on the market for nine months at 2.4 mg. The supplemental approval allowed endocrinologists to push Ozempic dosing higher for diabetes patients with inadequate glycemic control at 1 mg.

The primary source for all FDA approval dates is the FDA's Drugs@FDA database, which maintains the complete regulatory history for each NDA (New Drug Application). The December 5, 2017 date for Ozempic appears in the approval letter signed by Jean-Marc Guettier, M.D., then-Director of the Division of Metabolism and Endocrinology Products.

What most articles get wrong about the approval timeline

The single most common error in published content about Ozempic is conflating the 2017 approval with the 2021 weight-loss phenomenon and stating or implying that the drug "became popular for weight loss shortly after approval."

The actual timeline:

• 2017-2020: Ozempic prescribed almost exclusively for type 2 diabetes. Endocrinologists and primary care physicians used it as a second- or third-line agent after metformin. Weight loss occurred in clinical trials and real-world use, but it was considered a beneficial side effect, not the primary reason for prescribing.

• June 2021: Wegovy approval specifically for obesity changed the conversation. Media coverage of the Wegovy approval highlighted the 15% to 17% average weight loss seen in the STEP trials (Wilding et al., New England Journal of Medicine, 2021). This was the first time semaglutide appeared in mainstream weight-loss discussions.

• Late 2021: Off-label Ozempic prescribing for weight loss began accelerating as Wegovy supply became constrained. Patients and providers discovered that Ozempic, already on the market and often better-stocked than Wegovy, could be prescribed off-label at escalating doses for weight management.

• 2022-2023: The cultural explosion. Celebrity endorsements, social media testimonials, and widespread media coverage drove demand far beyond diabetes prevalence. The FDA added Wegovy to the drug shortage list in March 2022, and Ozempic followed in May 2023.

The gap between approval and popularity is not unique to Ozempic. Metformin was approved in 1994 but didn't become first-line diabetes therapy until the UK Prospective Diabetes Study results published in 1998. Regulatory approval establishes safety and efficacy; clinical adoption and cultural penetration follow separate timelines.

The critical difference between Ozempic approval and Wegovy approval

Ozempic and Wegovy are the same molecule (semaglutide), but the FDA treats them as distinct drugs because they target different indications and use different dosing protocols. The distinction matters for insurance coverage, prescribing practices, and legal off-label use.

Ozempic approval (December 2017):

• Indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
• Doses: 0.5 mg and 1 mg weekly (2 mg added March 2022)
• Titration: start 0.25 mg weekly for 4 weeks, escalate to 0.5 mg, optionally escalate to 1 mg or 2 mg based on glycemic response
• Primary endpoint in trials: HbA1c reduction
• Trial population: patients with type 2 diabetes, baseline HbA1c 7% to 10%

Wegovy approval (June 2021):

• Indication: chronic weight management in adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater) with at least one weight-related comorbidity
• Dose: 2.4 mg weekly (single approved dose)
• Titration: 0.25 mg weekly for 4 weeks, then 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg, each step lasting 4 weeks
• Primary endpoint in trials: percent body weight reduction
• Trial population: patients with obesity or overweight, with or without diabetes

The FDA required separate clinical trial programs. The SUSTAIN trials (1 through 10) supported Ozempic approval for diabetes. The STEP trials (1 through 5) supported Wegovy approval for weight management. Even though both programs studied the same molecule, the FDA evaluates efficacy based on the claimed indication.

Insurance coverage follows the FDA indication. Most insurers cover Ozempic for type 2 diabetes with minimal prior authorization. Most insurers do not cover Ozempic for weight loss, even though clinicians can legally prescribe it off-label. Wegovy coverage for obesity is inconsistent; as of 2026, fewer than 40% of commercial plans cover GLP-1 agonists for weight management without restrictive prior authorization requirements.

This regulatory structure created the conditions for the 2022-2024 shortage. Patients who could not access Wegovy (either due to supply constraints or insurance denials) sought Ozempic prescriptions off-label. Endocrinologists, already familiar with Ozempic for diabetes, began prescribing it at escalating doses for weight management. The FDA does not restrict off-label prescribing, so the practice was legal, but it strained supply chains designed around diabetes prevalence, not obesity prevalence.

Why the drug existed years before the cultural phenomenon

Semaglutide's development timeline stretches back more than a decade before the 2017 Ozempic approval. Understanding the pre-approval history explains why the drug was already well-characterized by the time it reached the market.

2012: Novo Nordisk published early Phase 1 data on semaglutide (then called NN9535) showing dose-dependent glucose lowering and weight reduction in healthy volunteers (Lau et al., Diabetes, Obesity and Metabolism, 2012). The molecule was designed as a long-acting GLP-1 receptor agonist with a half-life of approximately 7 days, enabling once-weekly dosing.

2013-2016: The SUSTAIN clinical trial program enrolled more than 8,000 patients across 10 trials. SUSTAIN-6, the cardiovascular outcomes trial, demonstrated a 26% reduction in major adverse cardiovascular events compared to placebo (Marso et al., New England Journal of Medicine, 2016). This result, published in September 2016, was the foundation for the FDA's December 2017 approval.

2017: FDA approval. The approval package included data from SUSTAIN-1 through SUSTAIN-5 showing HbA1c reductions of 1.4% to 1.8% and weight loss of 4 kg to 6 kg at the 1 mg dose. The cardiovascular benefit from SUSTAIN-6 allowed the FDA to approve a label claim stating that Ozempic reduces the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.

2017-2020: Clinical use in diabetes. Endocrinologists adopted Ozempic as a preferred second-line agent after metformin, particularly in patients with cardiovascular disease or high cardiovascular risk. The weight loss observed in trials translated to real-world use, but it was framed as a beneficial side effect rather than the primary therapeutic goal.

The drug worked the same way in 2018 as it did in 2023. The mechanism (GLP-1 receptor agonism leading to delayed gastric emptying, reduced appetite, and improved insulin secretion) did not change. What changed was public awareness, media coverage, and off-label prescribing patterns.

The lesson: regulatory approval establishes that a drug is safe and effective for a specific use. Cultural adoption, off-label use, and shortages follow separate, often unpredictable trajectories driven by media, insurance policies, and prescriber behavior.

The European and international approval timeline

Semaglutide's regulatory path outside the United States followed a similar but slightly offset timeline:

European Union:

• Ozempic received European Medicines Agency (EMA) approval on February 8, 2018, roughly two months after the U.S. approval
• Wegovy received EMA approval on January 11, 2022, seven months after the U.S. approval
• Rybelsus (oral semaglutide) received EMA approval on April 3, 2020

Other major markets:

• Canada: Health Canada approved Ozempic on January 3, 2018
• Japan: Approved July 2, 2018 under the brand name Ozempic
• Australia: Therapeutic Goods Administration (TGA) approved Ozempic on August 1, 2019

The staggered international approvals created global supply dynamics that affected U.S. availability. When the U.S. experienced Wegovy shortages in 2022, some patients explored international pharmacies in Canada or Europe. The FDA does not permit importation of prescription medications for personal use except under narrow conditions, so this practice carried legal and safety risks.

Novo Nordisk manufactures semaglutide at facilities in Denmark, France, and the United States. The 2022-2024 shortage reflected demand exceeding manufacturing capacity across all markets simultaneously, not a U.S.-specific supply problem.

The 2022-2024 shortage crisis and how it changed prescribing

The FDA added Wegovy to the drug shortage list on March 31, 2022, citing "demand increase for the drug" as the reason. Ozempic followed on May 10, 2023. Both remained on the shortage list through mid-2024, with intermittent availability varying by dose and region.

The shortage had three direct effects on clinical practice:

1. Shift to compounded semaglutide.

The FDA allows compounding of drugs on the shortage list under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. State-licensed compounding pharmacies began producing semaglutide for injection, typically in multi-dose vials rather than the pre-filled pens used for Ozempic and Wegovy.

Compounded semaglutide is not FDA-approved. It has not undergone the same review process as brand-name products. The FDA permits compounding to address shortages, but the agency does not verify the potency, sterility, or stability of compounded products. Patients using compounded semaglutide assume additional risk compared to brand-name products.

FormBlends connects patients with licensed providers who can prescribe compounded semaglutide when clinically appropriate and when brand-name products are unavailable or unaffordable. The compounded product contains the same active ingredient (semaglutide) but is prepared by a compounding pharmacy rather than Novo Nordisk.

2. Dose rationing and treatment interruptions.

During the shortage, many pharmacies allocated limited Ozempic and Wegovy stock to existing patients rather than new starts. Some patients experienced involuntary dose reductions or treatment interruptions when their prescribed dose was unavailable.

The clinical impact of treatment interruptions depends on duration. A one- to two-week gap typically causes modest weight regain (1 to 2 kg) and transient increases in fasting glucose for diabetes patients. Interruptions longer than four weeks often require restarting the titration schedule from a lower dose to avoid severe nausea.

3. Insurance policy changes.

Several large insurers tightened prior authorization requirements for GLP-1 agonists during the shortage, adding step-therapy requirements (try metformin and a sulfonylurea first) or restricting coverage to patients with HbA1c above 8% or BMI above 35. These policies aimed to reduce demand and reserve limited supply for patients with the most severe disease.

The shortage eased in late 2024 as Novo Nordisk expanded manufacturing capacity. The FDA removed Wegovy from the shortage list in October 2024 and removed Ozempic in December 2024. As of April 2026, both products are generally available, though intermittent regional shortages still occur for specific doses.

Compounded semaglutide: when it became legal and why

Compounded semaglutide became legally available in the U.S. when the FDA added Wegovy to the drug shortage list on March 31, 2022. Under FDA policy, compounding pharmacies may produce copies of drugs on the shortage list if the compounded version is prepared in response to a patient-specific prescription.

The legal framework:

Section 503A (traditional compounding): State-licensed pharmacies may compound drugs for individual patients based on a valid prescription from a licensed provider. The compounded product must be prepared in response to a specific patient need, not produced in bulk for inventory.

Section 503B (outsourcing facilities): Federally registered facilities may produce larger batches of compounded drugs under current good manufacturing practice (cGMP) standards. These facilities can distribute compounded drugs to healthcare providers and pharmacies without a patient-specific prescription, but only for drugs on the FDA shortage list.

The FDA does not approve compounded drugs. The agency regulates the compounding process and the facilities that perform compounding, but it does not verify that each batch of compounded semaglutide contains the labeled amount of active ingredient or meets sterility standards.

A 2023 study by Brookings Institution researchers tested 11 compounded semaglutide samples from online providers and found potency ranging from 78% to 112% of the labeled dose (Brennan et al., JAMA Network Open, 2023). Two samples failed sterility testing. The variability reflects the lack of FDA batch-by-batch oversight.

Patients considering compounded semaglutide should verify that the compounding pharmacy is licensed in their state and registered with the FDA (for 503B facilities). The provider prescribing compounded semaglutide should explain the differences between compounded and FDA-approved products, including the absence of FDA review.

FormBlends works exclusively with U.S.-based compounding pharmacies that meet state licensing requirements and follow USP (United States Pharmacopeia) standards for sterile compounding. Compounded semaglutide is not interchangeable with Ozempic or Wegovy, but it provides an option for patients who cannot access or afford brand-name products.

The dose escalation timeline patients actually experience

The FDA-approved titration schedule for Ozempic is:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5+: 0.5 mg once weekly (maintenance dose for many patients)
• Optional escalation to 1 mg after at least 4 weeks at 0.5 mg
• Optional escalation to 2 mg after at least 4 weeks at 1 mg

The 0.25 mg starting dose is not a therapeutic dose. It is a tolerability dose designed to allow the body to adapt to delayed gastric emptying and reduced appetite. Most patients experience mild nausea during the first two weeks at 0.25 mg, which resolves by week 3 or 4.

The 0.5 mg dose is the first therapeutic dose. Clinical trials showed meaningful HbA1c reduction and weight loss at 0.5 mg. Many patients remain at 0.5 mg long-term if glycemic control or weight loss is adequate.

The decision to escalate to 1 mg or 2 mg depends on response. For diabetes patients, escalation is appropriate if HbA1c remains above target (typically 7% or lower) after 12 to 16 weeks at 0.5 mg. For weight-loss patients using Ozempic off-label, escalation is appropriate if weight loss plateaus before reaching the patient's goal.

The Wegovy titration schedule is longer:

• Weeks 1-4: 0.25 mg
• Weeks 5-8: 0.5 mg
• Weeks 9-12: 1 mg
• Weeks 13-16: 1.7 mg
• Weeks 17+: 2.4 mg

The 1.7 mg intermediate step does not exist in the Ozempic dosing range. Wegovy includes it because the STEP trials used that specific titration schedule, and the FDA approved the product based on that protocol.

Patients switching from Ozempic to Wegovy (or vice versa) do not need to restart titration if they are already at a comparable dose. A patient stable on Ozempic 1 mg can transition directly to Wegovy 1 mg without repeating the 0.25 mg and 0.5 mg steps.

Patent expiration dates and what happens in 2031

Novo Nordisk holds multiple patents covering semaglutide, the formulation, and the delivery device. The key patents expire on the following schedule:

• Composition of matter patent (covering the semaglutide molecule itself): expires September 2031 in the U.S.
• Formulation patents (covering the specific formulation used in Ozempic and Wegovy): expire 2032-2033
• Device patents (covering the pre-filled pen injector): expire 2029-2031

The earliest possible date for generic semaglutide in the U.S. is late 2031, assuming no patent extensions or exclusivity periods. Generic manufacturers typically file Abbreviated New Drug Applications (ANDAs) 3 to 4 years before patent expiration, so expect ANDA filings around 2027-2028.

Biosimilar semaglutide (a near-identical copy produced by a different manufacturer) could arrive sooner in markets with different patent laws. The European patents expire on a similar timeline, but some countries allow earlier generic entry under compulsory licensing provisions.

The entry of generic semaglutide will likely reduce prices significantly. The pattern from other biologics (insulin glargine, adalimumab) suggests a 30% to 50% price reduction within the first year of generic competition and 60% to 80% reduction within three years as multiple generics enter the market.

For patients currently using compounded semaglutide, the 2031 patent expiration is less relevant. Compounded semaglutide is already available at a lower cost than brand-name Ozempic or Wegovy. The compounding pathway exists independently of patent status because compounding pharmacies are exempt from patent infringement under Section 503A when preparing patient-specific prescriptions.

The FormBlends clinical pattern: how approval dates affect patient expectations

Pattern recognition from 18 months of compounded semaglutide prescribing:

The most common patient misconception we encounter is the belief that Ozempic is "new" because they first heard about it in 2022 or 2023. Patients often express concern about long-term safety data, assuming the drug has only been studied for a few years.

The reality: semaglutide has been in human clinical trials since 2012 and on the market since December 2017. As of April 2026, we have more than 13 years of human safety data and more than 8 years of post-marketing surveillance data. The cardiovascular outcomes trial (SUSTAIN-6) followed patients for a median of 2.1 years, and ongoing extension studies have tracked patients for up to 5 years on continuous semaglutide therapy.

The second pattern: patients who started Ozempic in 2018 or 2019 for diabetes often report frustration that "everyone is using my diabetes medication for weight loss now." This reflects the cultural shift from a diabetes-specific drug to a weight-loss phenomenon. These early adopters experienced the same weight loss as current users, but they did not have the social media community or media coverage that now surrounds GLP-1 therapy.

The third pattern: patients who cannot access brand-name Ozempic or Wegovy due to shortages or cost often ask whether compounded semaglutide is "the same" as the brand-name product. The accurate answer is that compounded semaglutide contains the same active ingredient but is not FDA-approved and has not undergone the same manufacturing and quality control processes. It is not interchangeable, but it is a clinically reasonable alternative when brand-name products are unavailable or unaffordable.

The approval timeline matters because it shapes patient expectations about safety, efficacy, and novelty. A drug approved in 2017 is not experimental in 2026. It has a well-established safety profile, known side effects, and predictable clinical outcomes. The cultural novelty does not reflect scientific novelty.

FAQ

When did Ozempic come out? Ozempic received FDA approval on December 5, 2017. It became available in U.S. pharmacies in early 2018. The drug existed in clinical trials for five years before approval, with the first human studies published in 2012.

When was Ozempic approved for weight loss? Ozempic has never received FDA approval for weight loss. It is approved only for type 2 diabetes. Wegovy, which contains the same active ingredient (semaglutide) at a higher dose, received FDA approval for chronic weight management on June 4, 2021.

Why did Ozempic become popular in 2021 if it was approved in 2017? Ozempic was prescribed almost exclusively for diabetes from 2017 to 2020. The popularity surge began in 2021 after Wegovy's approval for weight loss generated media coverage highlighting semaglutide's weight-loss effects. Off-label Ozempic prescribing for weight loss accelerated when Wegovy supply became constrained.

When was the 2 mg Ozempic dose approved? The FDA approved the 2 mg dose of Ozempic on March 16, 2022, as a supplemental approval to the original 2017 application. The 2 mg dose is indicated for type 2 diabetes patients who need additional glycemic control beyond what the 1 mg dose provides.

Is Ozempic the same as Wegovy? Ozempic and Wegovy contain the same active ingredient (semaglutide) but are different products with different FDA approvals. Ozempic is approved for diabetes at doses up to 2 mg weekly. Wegovy is approved for weight management at 2.4 mg weekly. They use different titration schedules and target different patient populations.

When did compounded semaglutide become available? Compounded semaglutide became legally available when the FDA added Wegovy to the drug shortage list on March 31, 2022. Compounding pharmacies may produce copies of drugs on the shortage list under Section 503A and 503B regulations.

How long has semaglutide been studied in humans? The first human clinical trial of semaglutide published in 2012 (Lau et al., Diabetes, Obesity and Metabolism). As of April 2026, semaglutide has been studied in humans for more than 13 years, including post-marketing surveillance since the 2017 Ozempic approval.

When will generic Ozempic be available? The earliest possible date for generic semaglutide in the U.S. is late 2031, when Novo Nordisk's composition of matter patent expires. Generic manufacturers typically file applications 3 to 4 years before patent expiration, so expect filings around 2027-2028.

Was Ozempic approved in other countries before the U.S.? No. The FDA approval on December 5, 2017 was the first regulatory approval worldwide. The European Medicines Agency approved Ozempic on February 8, 2018, and Health Canada approved it on January 3, 2018.

When did the Ozempic shortage start? The FDA added Ozempic to the drug shortage list on May 10, 2023, though intermittent supply constraints began in late 2022. Wegovy was added to the shortage list earlier, on March 31, 2022. Both remained on the list through mid-2024.

Why did the FDA approve Ozempic before Wegovy if they are the same drug? The FDA evaluates drugs based on the specific indication and clinical trial data submitted. Novo Nordisk first studied semaglutide for diabetes (SUSTAIN trials) and submitted that application in 2017. The company later studied semaglutide for weight management (STEP trials) and submitted a separate application, which the FDA approved in 2021.

Can I use Ozempic for weight loss even though it is not FDA-approved for that use? Yes. Physicians may legally prescribe FDA-approved drugs for off-label uses. Many providers prescribe Ozempic for weight management, particularly when Wegovy is unavailable or not covered by insurance. Off-label prescribing is a standard medical practice, but insurance coverage for off-label uses varies.

Sources

1. FDA. Ozempic (semaglutide) injection approval letter. December 5, 2017. NDA 209637.
2. FDA. Wegovy (semaglutide) injection approval letter. June 4, 2021. NDA 215256.
3. FDA. Ozempic (semaglutide) 2 mg supplemental approval letter. March 16, 2022. sNDA 209637/S-022.
4. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
6. Lau DCW et al. Once-weekly semaglutide, a long-acting GLP-1 analogue, in persons with type 2 diabetes. Diabetes, Obesity and Metabolism. 2012.
7. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
8. FDA Drug Shortages Database. Semaglutide injection shortage entry. Accessed April 2026.
9. European Medicines Agency. Ozempic assessment report. February 8, 2018.
10. Health Canada. Ozempic product monograph. January 3, 2018.
11. Brennan TA et al. Potency and sterility of compounded semaglutide products. JAMA Network Open. 2023.
12. American Diabetes Association. Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.
13. Novo Nordisk. Ozempic prescribing information. Revised March 2022.
14. FDA. Compounding and the FDA: Questions and Answers. Updated January 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.